Compared with the AD patients without end-point events, the AD patients with end-point events exhibited higher SFRP1, SFRP2, SFRP3, and SFRP4 levels and lower SFRP5 concentrations (Figures 2A–E). This evidence concerns the gene SFRP1 and Alzheimer disease.